Evidence map›Paper›PMID 28585153›Full record

SynthesisDrug safety2017

Second-Generation Antipsychotics and Metabolic Side Effects: A Systematic Review of Population-Based Studies.

Lauren Hirsch, Jaeun Yang, Lauren Bresee, Nathalie Jette, Scott Patten, Tamara Pringsheim

Abstract readComparative StudySystematic Review
PubMed Publisher
In one paragraph

Synthesis in Drug safety, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 83 papers, 5 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
83citing papers in PubMed, 5 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

83 citing papers in PubMed, 5 syntheses or guidelines pooled it.

  1. Dose-Dependent efficacy and safety of Brexpiprazole in agitation associated with dementia in Alzheimer's disease: A systematic review and meta-analysis.Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology · 2026
    Pooled it
  2. Pooled it
  3. Pooled it
  4. Pooled it
  5. Pooled it
  6. Trial
  7. Article
  8. Review
  9. Pharmaceuticals (Basel, Switzerland) · 2026
    Article
  10. Article
  11. Article
  12. Integrative multi-omics identifiesPsychological medicine · 2026
    Article
  13. Review
  14. Article
  15. Article
  16. Review
  17. Article
  18. Article
  19. Article
  20. Observational

23 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Lauren HirschDepartment of Community Health Sciences, University of Calgary, Calgary, AB, Canada.ORCID 0000-0002-8649-9943
Jaeun YangDepartment of Clinical Neurosciences, University of Calgary, Calgary, AB, Canada.
Lauren BreseeDepartment of Community Health Sciences, University of Calgary, Calgary, AB, Canada.
Nathalie JetteDepartment of Community Health Sciences, University of Calgary, Calgary, AB, Canada.
Scott PattenDepartment of Community Health Sciences, University of Calgary, Calgary, AB, Canada.
Tamara PringsheimDepartment of Clinical Neurosciences, Psychiatry, Pediatrics and Community Health Sciences, University of Calgary, Mathison Centre for Mental Health Research and Education, 3280 Hospital Drive NW, Calgary, AB, T2N 4Z6, Canada. tmprings@ucalgary.ca.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

introductionThere is strong evidence from randomized controlled trials (RCTs) that second-generation antipsychotic (SGA) medications are associated with metabolic adverse events. However, with the recent increases in the use of SGAs worldwide and frequent off-label use, it is unclear whether these associations are generalizable to populations beyond those included in RCTs.

objectivesThis review aims to characterize the impact of SGAs on the population through a systematic review of population-based studies of SGA users. Studies could examine the use of any SGA medication and any comparator group. Studies also needed to include at least one metabolic outcome such as type 2 diabetes mellitus, dyslipidemia, obesity, hypertension, or metabolic syndrome.

methodsA systematic search process was used to identify studies for inclusion in this review. Included studies had to be population-based studies of users of any SGA medication with at least one reported metabolic outcome. Study quality was also assessed using the AMSTAR tool, and evidence was synthesized by both metabolic outcome and specific SGA medication.

resultsIn total, 15 studies were included in this review. Type 2 diabetes mellitus was the most frequently reported outcome; clozapine and olanzapine were most strongly associated with type 2 diabetes mellitus. Evidence was mixed for a moderate association between type 2 diabetes mellitus and risperidone or quetiapine. Few studies examined other metabolic outcomes, and therefore it is difficult to estimate the true effect in the population. DISCUSSION: Population-based evidence for other SGAs and metabolic outcomes was limited. However, clozapine and olanzapine were consistently more strongly associated with metabolic adverse events than were other SGAs currently available.

Indexed as

Research DesignAntipsychotic AgentsBenzodiazepinesClozapineHumansMetabolic DiseasesOlanzapineRandomized Controlled Trials as TopicAntipsychotic AgentsBenzodiazepinesClozapineOlanzapine

Identifiers

PMID28585153

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.